PolyPid Ltd. (PYPD)
NASDAQ: PYPD · IEX Real-Time Price · USD
4.484
-0.006 (-0.13%)
Apr 23, 2024, 3:57 PM EDT - Market closed
Company Description
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
PolyPid Ltd.
| Country | Israel |
| Founded | 2008 |
| IPO Date | Jun 26, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Ms. Dikla Czaczkes Akselbrad |
Contact Details
Address: 18 Hasivim Street Petach Tikva, L3 495376 Israel | |
| Phone | 972-74-7195700 |
| Website | polypid.com |
Stock Details
| Ticker Symbol | PYPD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001611842 |
| CUSIP Number | M8001Q118 |
| ISIN Number | IL0011326795 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dikla Czaczkes Akselbrad | Chief Executive Officer and Director |
| Jonny Missulawin | Chief Financial Officer |
| Dalit Hazan | Executive Vice President of Research & Development and Clinical and Regulatory Affairs |
| Ori Warshavsky | Chief Operating Officer - US |
| Maria Rubin | Vice President of Operations |
| Tal Vilnai | General Counsel and Corporate Secretary |
| Rivi Lev-ari | Vice President of Human Resource |
| Dr. Jean-Marc Hagai Pharm.D. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | 6-K | Report of foreign issuer |
| Feb 13, 2024 | EFFECT | Notice of Effectiveness |
| Feb 9, 2024 | UPLOAD | Filing |
| Feb 1, 2024 | F-3 | Filing |